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Abstract
Purpose Opioid treatment of non-malignant chronic pain can
result in hypoxemia, hypercarbia, and central sleep apnea. The
aim of this study was to determine the initial efficacy of auto
servo-ventilation (ASV) and after 3 months of home use.
Methods This prospective multicenter interventional study re-
cruited chronic pain patients prescribed ≥100morphine equiv-
alents for at least 4 months.
Participants Following full-night polysomnography (PSG) to
confirm the presence of sleep-disordered breathing, patients
were randomized to three additional full-night-attended PSGs
with continuous positive airway pressure (CPAP), ASV, and
servo-ventilation with an initial mandatory pressure support of
6 cm H2O (ASV manual PSmin 6). Following the PSGs, pa-
tients were sent homewith EncoreAnywhere and ASVwith or
without mandatory pressure support.
Results Based on the initial PSG studies, CPAP improved but
did not normalize the apnea-hypopnea index (AHI), central
apnea index (CAI), or hypopnea index (HI), as all remained
elevated. Clinically significant reductions were noted after just
one night of ASVand ASVmanual (PSmin 6). After 3 months
of ASV home use, the AHI, CAI, and obstructive apnea index
(OAI) were significantly reduced when compared to baseline
diagnostic levels and even when compared to respiratory dis-
turbance indices with CPAP treatment.
Conclusions Initial and home use of ASV for 3 months re-
sulted in significantly lower AHI, CAI, and OAI. This reduc-
tion attests to the efficacy of ASV treatment in chronic pain
patients on high doses of opioids.
Keywords Chronic pain . Opioids .
Sleep-disordered breathing . ASV
Introduction
The Institute of Medicine Report on Pain [1] recognizes
chronic pain as a public health challenge affecting over 100
million Americans. A statement from the American Academy
of Pain Medicine [2] supports opioid treatment for chronic
non-malignant pain where medically indicated, when more
conservative treatments are ineffective, and if accompanied
by ongoing medical monitoring. In 2009, there were close to
80 million prescriptions for opioid analgesics in the USA,
with 45.7 % of all opioid prescriptions going to individuals
in the age range of 40 to 59 years old [3]. Of note, this age
grouping is also associated with an increased risk of develop-
ing obstructive sleep apnea (OSA) [4].
Sleep-disordered breathing (SDB) is an all-inclusive term
that includes OSA, central sleep apnea (CSA), and mixed
apnea (both OSA and CSA). OSA is a condition where there
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is intermittent partial or complete obstruction of the upper
airway during sleep that limits or prevents airflow despite
continued efforts to breathe. CSA is a condition where breath-
ing is interrupted by the lack of respiratory effort. SDB is
characterized by apneas and hypopneas that result in gas ex-
change abnormalities (hypoxemia, hypercapnia, and
hypocapnia), arousal from sleep, and excessive daytime
sleepiness. Individuals with undiagnosed and untreated
SDB are at greater risk of increased morbidity [5] and
mortality [6]. It is estimated that a significant proportion
of individuals with OSA, especially those in primary
care, remain undiagnosed [7].
Opioids are prescribed to treat chronic pain in up to 90% of
pain management clinic patients [8]. Although opioids are
effective in the long-term management of chronic non-
malignant pain [9], opioid use in patients with chronic pain
was found to be a significant, dose-dependent predictor for the
emergence of CSA and ataxic breathing [10, 11]. In addition
to reduced ventilatory responsiveness to hypercarbia and hyp-
oxemia [12], opioids may reduce upper airway tone predis-
posing the airway to instability and collapse [13]. The decline
in EMG activity in the pharyngeal dilator muscles at sleep
onset is much greater in patients with OSA as compared to
healthy controls [14], suggesting that long-term opioid use
could pose a particularly significant risk to patients with un-
diagnosed OSA. Jungquist and colleagues [11] did not find an
exacerbation of OSA symptoms with opioid treatment, but the
findings from this lone study require replication.
It is estimated that between 30 and 90 % of patients using
opioids have sleep-disordered breathing [10]. In a case study
of three patients on sustained-release opioids for chronic pain,
Farney and colleagues [15] reported distinct patterns of SDB
including ataxic breathing, CSA, sustained hypoxemia, and
prolonged obstructive hypopneas. In contrast to what is typi-
cally observed in patients with OSA, apnea duration and hyp-
oxemia were more severe and respiratory disturbances were
longer in duration in NREM sleep compared to rapid eye
movement (REM) sleep.
Continuous positive airway pressure (CPAP) therapy re-
mains to be the standard first-line and effective treatment for
OSA. CPAP, when titrated to the appropriate pressure, pro-
vides a positive pressure splint to prevent airway collapse and
hence prevent the obstruction of the upper airway during
sleep. Even though CPAP is highly effective in treating
OSA, it has been considered an insufficient therapy for
CSA, central apneas and hypopneas, and even periodic breath-
ing that arises with CPAP treatment [16]. Although there is
documentation of resolution of CPAP-emergent central apneic
activity in some patients, this is not the case for all [17]. Fur-
ther, Cassel and colleagues [18] noted the appearance of cen-
tral apneas in patients with OSA on CPAP treatment despite
no such activity being present during initial titration with a
CPAP device.
A number of studies have demonstrated that CPAP therapy
effectively abolishes obstructive apneic events but is not as
effective in treating central apneas in patients with heart failure
or those on opioid medications [19, 20]. In fact, in patients
taking opioids, both central and obstructive events may be
present throughout the night, and in some cases, the applica-
tion of CPAP treatment results in an increase in the number of
central respiratory events [21].
Adaptive servo-ventilation (ASV) therapy has been shown
to normalize respiration in patients with Hunter-Cheyne-
Stokes respiration in conjunction with heart failure [22] and
in patients with persistent CSA despite CPAP treatment [19].
CSA is a common occurrence in patients with heart failure
[23], and ASV therapy has been shown to improve prognosis
in this patient population [24]. ASV has also been shown to be
an effective counter to treat complex sleep apnea syndrome, a
situation where central events emerge during CPAP titration
for treatment of OSA [25].
Conflicting results have been published about the efficacy
of ASV in treating SDB associated with opioid use. In a 2008
study, ASV was unsuccessful in treating SDB in patients on
chronic opioid therapy [21]. The study results demonstrated
that with ASV therapy, obstructive apneas decreased, while
hypopneas increased and central apneas were reduced com-
pared to baseline, but not significantly so. The latter may have
occurred as a consequence of applying inadequate settings on
the ASVmachines utilized in the study, as the authors reported
using the default settings for the end-expiratory pressure, min-
imum inspiratory pressure support, maximum inspiratory
pressure support, and backup respiratory rate [21]. Further,
ASV algorithms were initially designed to manage Cheyne-
Stokes respiration (CSR) where there is a cyclical increasing
and decreasing airflow pattern. Opioids may induce a less
cyclical pattern, and the ASV algorithm used in the study by
Farney [21] may not have adequately responded to a more
variable breathing pattern. In contrast, the study by Javaheri
[20] demonstrated that ASV was effective in the treatment of
SDB in five patients on chronic opioids by significantly re-
ducing both obstructive and central apneas as compared to
CPAP. Similarly, Ramar and colleagues [26] found ASV to
be equally effective in treating CSA and complex sleep apnea
in 108 patients with chronic heart failure as well as those on
chronic opioid therapy.
The above findings are a promising indicator for the effec-
tiveness of ASV in patients with SDB associated with chronic
opioid therapy but are not without significant limitations. In-
formation is available for the comparative effectiveness of
ASV and CPAP only for the initial night of treatment. It re-
mains unknown whether the improved efficacy of ASVover
CPAP treatment is sustained throughout months of therapy.
Further, only the study by Javaheri [20] investigated patients
with chronic pain disorders taking >100 mEq of opioid med-
ication, but the extremely small patient sample size in that
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study limits the generalizability of the findings. More impor-
tantly, the participants in all of the above studies were recruit-
ed only from those referred for diagnostic evaluation of sleep
apnea. These patients are quite probably those with more se-
vere SDB and are likely not representative of most patients
taking chronic opioid medications. Therefore, the efficacy of
ASV versus CPAP therapy needs to be investigated over
months of treatment in a study with a sufficient sample size
and comprised of patients that are representative of the popu-
lation of chronic pain patients being treated with opioids.
The primary aim of this study was to determine the ability
of ASV therapy to correct sleep-disordered breathing with a
significant central apnea component in participants with
chronic pain who are treated with opioids and are naïve to
positive pressure therapy. The study was designed to deter-
mine if ASV treatment improved arterial oxygen saturation
during sleep and to elucidate if there is a relation between
prescribed opioid dose and SDB measures.
Methods
The System One BiPAP® autoSV Advanced (ASV, Philips
Respironics) provides non-invasive ventilation in adult pa-
tients with SDB including CSR, CSA, and OSA. The ASV
modulates inspiratory positive airway pressure (IPAP) accord-
ing to the patient’s breathing pattern using an internal algo-
rithm. The IPAP levels are automatically adjusted on a breath-
by-breath basis in order to help stabilize the amount of air
being inhaled. The ASValso provides an auto-adjusting expi-
ratory positive airway pressure (EPAP) feature. The auto-
adjusting EPAP is controlled using the device to treat airway
instability or obstruction. The auto-adjusting EPAP feature
includes identification of open (presumed to be central ap-
neas) and closed (presumed to be obstructive) airway events
as a critical element of its therapeutic benefits. An automatic
backup rate tracks spontaneous breathing and provides an
effective backup rate of 2 to 3 breaths per min below the
spontaneous rate. The auto backup rate is designed to assure
a rate closer to the patient’s normal rate and avoid over-
ventilating the patient.
The aim of this study was to investigate the efficacy of the
ASV with mandatory pressure support (ASV manual PSmin
6) and without mandatory pressure support (ASV) as com-
pared to CPAP, during in-laboratory studies. This study intro-
duced two control measures to promote efficacious treatment
in anticipation of the decrease in respiratory drive produced by
opioids. For the first control measure, the ASV device was
modified to deliver a minimum minute ventilation of approx-
imately 5 l. The ASV manual with mandatory pressure sup-
port (the second control measure) started at a minimum pres-
sure support of 6 cm H2O (ASV manual PSmin 6) and was
adjusted upwards as needed. The ASV (without mandatory
pressure support) was set at factory settings. The eligibility
criteria for the study are listed in Table 1. After the diagnostic
polysomnography (PSG), those with an apnea-hypopnea in-
dex (AHI) of ≥20 and central apnea index (CAI) ≥10 events
per h of sleep or at least 25 % of total sleep time (TST) below
90% SaO2 and AHI ≥10 were asked to continue to participate
in the study.
Research ethics approval was obtained for this multisite
study. The full study consisted of three phases: screening, in-
laboratory treatment PSGs, and 3-month device take-home
evaluation. After signing informed consent, demographic data
were collected and recorded. A medical history including pain
diagnoses and a detailed medication assessment, including the
names, frequencies, and dosages of all current medications,
were performed. This multisite study involved six sleep
clinics (five in the USA and one in Canada).
Participants were instructed to medicate themselves as pre-
scribed prior to and during the screening PSG and all subse-
quent PSGs. Overnight diagnostic PSGs were performed
using standard parameters and were scored based on standard
criteria [27] at one central location. Participants who met eli-
gibility criteria demonstrating an AHI of at least 20 and a CAI
of ≥10, an OR of at least 25 % of TST below 90 % SaO2, and
an AHI ≥10 were enrolled in the therapy phase of the study
and randomized to each of the following full-night in-lab PSG
titrations: CPAP, ASV, and ASV manual (PSmin 6). All ther-
apy PSGs were scheduled within 1 week of each other, but not
on consecutive nights. The CPAP starting pressure was
4 cm H2O and was increased 1 cm H2O for obstructive events
associated with snoring, apneas, and hypopneas to a maxi-
mum CPAP pressure of 15 cm H2O (or as determined by the
physician). The settings of the ASVand ASV manual (PSmin
6) are shown in Table 2.
Based on the investigator’s interpretation and review of the
three centrally scored therapy PSGs at each study site, each
participant was asked to take home either an ASV device or a
CPAP device to use for 3 months. The device settings were
determined by the investigator based on the centrally scored
results. Participants were asked to return to the sleep center for
follow-up visits after 1 and 3 months. All take-home devices
were equipped with a modem and an SD card. The daily
device data were uploaded into EncoreAnywhere™ (Philips
Respironics) during the 3-month at-home portion of the study,
in order to assess adherence, therapy pressures, and device-
output respiratory indices.
Polysomnographic endpoints were compared between the
three treatment arms: CPAP, ASV, and ASV manual (PSmin
6). Due to the asymmetric distributions of the endpoints, the
nonparametric Friedman analysis of variance was used to
compare the related values obtained from the three therapy
PSGs. Post hoc pairwise comparisons were performed using
the Wilcoxon signed-rank test, with Bonferroni correction.
The daily data collected from EncoreAnywhere were
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averaged within each participant. To calculate an unbiased
participants’ average of therapy pressure and respiratory indi-
ces, the daily values were weighted relative to each day’s
device usage. The 3-month follow-up data from the ASV
and ASV manual (PSmin 6) groups were merged as the respi-
ratory variables from patients using these devices were not
significantly different (see Table 5). The 3-month averages
of AHI, CAI, obstructive apnea index (OAI), and hypopnea
index (HI) for study participants using ASVwere compared to
the respective measures from the CPAP titration using the
Wilcoxon signed-rank test. p values <0.05 were considered
significant. Where applicable, data in the study are expressed
as median (mean±standard deviation).
Results
The details of the patient flow throughout the study are found
in Table 3. Randomized study participants, 19 females (56 %)
and 15 males, were 50.7±11.6 years old and had a BMI of
30.1±5.4 kg/m2, and racial composition was 91 % (31) Cau-
casian and 9 % (3) African-American. On average, study par-
ticipants were on 390.1±338.1 mEq of morphine (range 100–
1700 mEq). Forty-seven percent (35/74; Table 3) of the par-
ticipants screened had SDB. Patient demographic data for the
total study group and for those participants who completed
and those who discontinued the study are shown in Table 4.
Compared to treatment with CPAP (Table 5), pairwise com-
parisons revealed clinically significant reductions in apnea-
hypopnea index (AHI), central apnea index (CAI), and OAI
after just one night of ASV and ASV manual (PSmin 6) use.
Improvement in respiratory variables did not differ between
treatment with ASV without mandatory pressure support or
ASV manual (PSmin 6) with mandatory pressure support.
Table 1 Participants’ selection
criteria Inclusion criteria Exclusion criteria
Males and females, ages 21–70
Able and willing to provide written informed consent
Diagnosis of chronic non-malignant pain (pain present
for ≥6 months)
Stable regimen of opioids (oral, transdermal, and/or
intravenous) for chronic pain for at least 4 weeks
prior to study participation with a prescribed opioid
dose equal to at least 100 mEq of morphine per 24 h
Agreement to undergo an in-lab Diagnostic
polysomnography (PSG) demonstrating an AHI of
at least 20 and CAI ≥10 events per h of sleep, OR at
least 25 % of TST below 90 % SAO2 saturation
and AHI ≥10
Agreement to undergo 3 full-night, in-lab PSGs on
positive airway pressure therapy
Agreement to undergo breathalyzer testing prior to
each PSG visit
Ability to provide reliable documentation of opioid
medications (e.g., pharmacy records) as treatment
for chronic pain for the previous 30 days
Willingness to undergo urine drug screening
Participation in other interventional, sleep, or
pharmaceutical-related research studies within 30
days prior to giving consent
Workers with variable shift schedules
Previous treatment with positive airway pressure
therapy within 90 days of providing consent
Participants with any conditions in which positive
airway pressure is medically contraindicated
BMI >40
Unwilling to wear PAP
Any surgery involving the upper airway, eye, nose,
sinuses, or middle ear within the last 90 days
Major or poorly managed medical or psychiatric
condition that would interfere with the demands
of the study, the use of positive airway pressure,
or the ability to complete the study
Previous diagnosis of severe COPD with an FEV1
<1 l or less than 50 % predicted
Presence of elevated arterial carbon dioxide levels
while awake (PaCO2≥50 mmHg) due to intrinsic
lung disease or neuromuscular or musculoskeletal
disorders
Participants currently prescribed with 24-h oxygen
therapy
Table 2 AutoSV device settings





















Rate setting Auto Auto
Rise time 2 2
Humidification 2 2
BiFlex Off Off
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Table 6 presents the PSG sleep architect variables during
the four PSG studies: one diagnostic study and three titration
studies that were performed in counterbalanced order. Arousal
index was found to be significantly (p=0.021) greater during
ASV manual (PSmin 6) titration compared to the CPAP titra-
tion night. No significant differences were noted for CPAP
versus ASV (p=0.288) or ASV versus ASV manual (PSmin
6) (p>0.99). No further differences in the other PSG variables
were seen across the three treatment PSGs.
Following the PSG phase of the study, 30 participants
started the at-home phase. Per the decision of the individual
site investigators, four study participants (13.3 %) went home
with ASV manual (PSmin 6), and the majority (21 partici-
pants, 70 %) used ASV for 3 months at home. Data for home
use of ASVand ASV manual (PSmin 6) were combined. Five
participants (16.7 %) were sent home with CPAP machines.
Data from these latter participants will be presented elsewhere.
Among the 25 participants who started the at-home phase
using ASV therapy, one study participant did not use the
device and was subsequently lost to follow-up. After 3 months
of ASV home use (Table 7), the AHI, CAI, and OAI were all
significantly (p<0.001) reduced when compared to respiratory
disturbance indices during the in-laboratory CPAP titration.
Adherence statistics were calculated based on participants’
entire 3-month at-home period or their projected 3-month visit
date (if they discontinued). The one study participant who did
not use their device was included in the intention-to-treat anal-
ysis. Adherence to both ASVand CPAP treatment is shown in
Table 7. Overall, the ASV devices were used for 49.8±36.1 %
of the days of home treatment with participants using their
machines for four or more hours on 30.9±32.8 % of the days
(N=25).
Discussion
This study is the first to report on both the acute and 3-
month impact of ASV treatment of SDB in participants
with chronic pain taking 100 or more milliequivalents
of opioid medication. The design of this study has over-
come some of the limitations of previous studies [21,
26]. Specifically, the participants in the current study
had not been previously referred for investigation of a
sleep breathing disorder and were recruited from chronic
pain clinics, not from sleep clinics.
A large epidemiological study estimates that the point prev-
alence of at least one chronic painful disorder is about 1 in five
individuals [28]. Given that the majority of individuals with
sleep apnea remain undiagnosed [29], the findings of this
study have implications for the routine clinical screening for
SDB in participants with chronic pain being treated with high-
dose opioids. Given that almost half of the study participants
were found to have SDB, routine screening for SDB among
chronic pain patients is likely to become evenmore of an issue
based on the 2013 statement from the American Academy of
Pain Medicine supporting the use of opioids to treat chronic
pain combined with reports of increased mortality rates in
those taking opioid medications [30].
A previous unpublished investigation found that about one
third of participants in a chronic pain clinic spent about one
third of the night below 90 % SaO2. ASV manual with man-
datory pressure support (PSmin 6) was applied to address
issues with decreased respiratory drive in this patient popula-
tion. For this study, ASV manual (PSmin 6) (with mandatory









Age (years) 50.7±11.6 52.5±7.9 46.9±16.8
Gender distribution
Females 28 14 9
Males 11 5 6
BMI (kg/m2) 30.1±5.4 30.7±5.0 28.9±6.4
Race distribution
Caucasian 31 20 11




Min 100 100 100
Max 1700 812.5 1700
Major diagnoses included arthritis, back/spine/neck injury, chronic pain
secondary to a medical or neurological condition, and headaches/mi-
graines. There were no differences in the demographics between those
participants who completed and those who discontinued the study (age:
p=0.32; BMI: p=0.43; mEq: p=0.85)
Table 3 Participants’ flow throughout the study
Males Females Total
Completed study part I: diagnostic PSG
screening
31 43 74
Met the criterion AHI of at least 20
and a CAI of ≥10
10 12 22
Met the criterion of at least 25 % of
TST below 90 % SaO2 and AHI ≥10
3 5 8
Met both criteria 2 3 5
Failed both criteria 16 23 39
Randomized for the study (fulfilled
inclusion/exclusion criteria)
15 19 34
Completed study part 2: titration with
CPAP, ASV manual (PSmin 6),
and ASVauto
13 18 31
Completed study part 3: 3-month at-home
treatment with ASV (auto or manual)
8 11 19a
a From the 25 who started the at-home treatment phase of the study with
ASVauto or ASV manual (PSmin 6), there were 19 completers
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pressure support) had no benefit over ASVwithout mandatory
pressure support in treating sleep-disordered breathing. ASV
use during the initial titration and during the 3 months of home
use resulted in significantly lowered AHI, CAI, and OAI. The
low treatment adherence rate during the ASV home-use phase
of this study is of concern and a limitation of this study but is
in line with the low CPAP adherence rates reported in the
literature [31, 32]. As study participants had not previously
recognized that they had a SDB, they may not have come to
terms with having a sleep disorder and may not have seen the
need for the treatment of their SDB. Participants’ attitude and
beliefs have been shown to greatly impact treatment adher-
ence [33], and patient education is crucial for promoting
adherence to treatment for SDB [34, 35]. As such, the imple-
mentation of ASV treatment adherence strategies, including
educational sessions and distribution of educational materials,
should be considered for this patient population. Anecdotally,
we have noted clinically that a tailor-made short educational





















AHI 32.5 (38.8±31.1) 10.1 (17.4±20.1) 1.4 (4.5±7.3) 2.1 (7.6±16.7) <0.001 <0.001 0.009 >0.99
CAI 6.4 (16.1±18.8) 2.4 (8.4±12.4) 0.0 (0.2±0.8) 0.0 (0.2±0.9) <0.001 <0.001 <0.001 >0.99
OAI 1.9 (9.7±15.2) 2.8 (4.5±6.3) 0.0 (0.3±0.5) 0.0 (0.5±1.1) <0.001 <0.001 <0.001 >0.99
HI 10.2 (14.8±12.6) 2.8 (4.5±5.1) 1.4 (4.6±7.4) 3.2 (7.9±16.2) 0.441 – – –
ODIa 24.2 (32.8±29.2) 6.0 (15.1±20.2) 1.9 (5.9±8.6) 2.6 (9.5±19.2) 0.161 – – –
Av. O2
saturation
93.4 (92.9±3.4) 94.9 (94.6±2.3) 94.6 (94.6±2.6) 94.6 (94.5±3.2) 0.627 – – –
Min. O2
saturation
80.5 (79.9±7.8) 85.0 (85.5±6.0) 85.0 (82.9±16.2) 86.6 (79.7±22.8) 0.991 – – –
Data are expressed as median (mean±standard deviation). The above p values for the pairwise comparisons, using the Wilcoxon signed-rank test, have
undergone Bonferroni adjustment
HI hypopnea index, ODI oxygen saturation index
aDefined as the number of times per hour that the oxygen saturation dropped below 4 % of baseline
Table 6 Comparison of PSG sleep architectural variables across diagnostic PSG and titration study (CPAP, ASV, and ASV manual (PSmin 6)) nights
Diagnostic PSG
(N=31)




Arousal index 20.3 (22.9±13.8) 11.8 (14.9±8.0) 16.6 (17.7±9.4) 16.1
(19.2±11.7)
0.028a
Total sleep time (TST) (min) 407.0 (409±57.8) 387.0 (386.8±60.2) 376.5 (377.6±85.0) 385.0 (380.4±67.2) 0.798
Sleep efficiency (%) 89.1 (87.9±8.3) 90.0 (86.8±9.7) 87.7 (83.3±13.9) 86.7 (84.9±10.2) 0.419
Wake after sleep onset (min) 39.6 (47.4±33.5) 37.1 (50.6±40.6) 45.8 (62.3±50.9) 51.2
(59.0±42.1)
0.313
Stage 1 (% TST) 7.8 (11.0±10.2) 5.6 (8.4±6.9) 6.8 (9.2±8.5) 7.3 (9.4±7.0) 0.201
Stage 2 (% TST) 70.9 (73.3±13.0) 78.3 (76.2±12.2) 74.3 (73.2±11.1) 78.1
(77.0±11.2)
0.206
Stage 3/4 (% TST) 0.2 (4.3±7.1) 0.8 (3.6±5.8) 0.6 (5.3±9.5) 0.3 (3.3±5.8) 0.296
REM (% TST) 11.2 (11.4±8.3) 9.3 (11.8±9.1) 10.3 (12.3±9.4) 8.3 (10.3±8.0) 0.407
Sleep onset latency (min) 4.0 (9.0±12.1) 4.6 (8.8±10.5) 4.3 (12.9±28.4) 4.0 (9.0±13.6) 0.575
Data are expressed as median (mean±standard deviation)
a Pairwise comparisons, using the Wilcoxon signed-rank test and undergoing Bonferroni adjustment, indicated that the arousal index was significantly
(p=0.021) greater during ASV manual (PSmin 6) titration compared to CPAP. No significant differences were noted for CPAP versus ASV manual
(PSmin 6) (p=0.288) or ASV versus ASV manual (PSmin 6) (p>0.99)
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booklet [35] providing information about CPAP can improve
compliance and a similar booklet for this population would be
strongly encouraged. However, our finding that respiratory
indices were significantly improved with ASV treatment
despite the low adherence rates attests to the unique efficacy
of ASV treatment of SDB in chronic pain participants on high
doses of opioids.
A significant limitation of this study is the high dropout
rate. Of the 34 participants recruited, 31 completed the in-
laboratory testing, but only 19 (44 % were either dropouts or
were treated with CPAP) completed the 3-month at-home
treatment phase. Intention-to-treat analyses were employed
in this study to help reduce the impact of the dropouts on the
study data. Further, although the only significant improve-
ment in sleep architecture with treatment was a reduction in
the arousal index; the arousal index was slightly higher with
ASV manual PSmin 6 when compared with CPAP treatment.
Slow-wave sleep levels were extremely low on the diagnostic
night and did not improve with treatment. This alteration in
sleep architecture is a likely consequence of the high
milliequivalents taken by the study patients and the fact that
opioid drugs suppress slow-wave sleep [36]. Others have also
provided evidence that opioid use decreases slow-wave sleep
in both healthy adults [37] and individuals with chronic pain
[38].
It should be noted that the respiratory indices for the at-
home study phase were recorded using the automatic event
detection algorithm in EncoreAnywhere. A previous report
[39] documented a strong and significant correlation (intra-
class correlation=0.8, p<0.001) for AHI and AI recorded by
PSG when compared to automatic event detection of respira-
tory events using a positive airway pressure device. The
device’s algorithm did not differentiate obstructive from central
events. The correlation for the HI was significant, but much
lower (intra-class correlation=0.3, p<0.001).
The vicious cycle linking chronic pain and sleep distur-
bances is well established [40, 41]. Treatment of SDB in par-
ticipants with chronic pain and on opioid therapy may reduce
morbidity and mortality as a consequence of untreated SDB.
A future publication from additional data collected during this
study will document whether a treatment of SDB can lead to
improvements in sleep, reduce pain levels, and improve day-
time sleepiness, fatigue, and poor alertness.
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Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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